Contrasting of vTv Therapeutics Inc. (VTVT) and Melinta Therapeutics Inc. (NASDAQ:MLNT)

As Biotechnology companies, vTv Therapeutics Inc. (NASDAQ:VTVT) and Melinta Therapeutics Inc. (NASDAQ:MLNT) are our subject to contrast. And more specifically their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
vTv Therapeutics Inc. 12.43M 8.68 8.65M -0.78 0.00
Melinta Therapeutics Inc. 65.17M 0.97 133.95M -21.57 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of vTv Therapeutics Inc. and Melinta Therapeutics Inc.

Profitability

Table 2 provides vTv Therapeutics Inc. and Melinta Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
vTv Therapeutics Inc. -69.59% 10% -75.9%
Melinta Therapeutics Inc. -205.54% -69.8% -33.4%

Volatility & Risk

vTv Therapeutics Inc. has a -3.68 beta, while its volatility is 468.00% which is more volatile than Standard and Poor’s 500. Competitively, Melinta Therapeutics Inc.’s beta is 2.26 which is 126.00% more volatile than Standard and Poor’s 500.

Liquidity

The current Quick Ratio of vTv Therapeutics Inc. is 0.2 while its Current Ratio is 0.2. Meanwhile, Melinta Therapeutics Inc. has a Current Ratio of 1.3 while its Quick Ratio is 1. Melinta Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than vTv Therapeutics Inc.

Institutional & Insider Ownership

The shares of both vTv Therapeutics Inc. and Melinta Therapeutics Inc. are owned by institutional investors at 3% and 61.9% respectively. vTv Therapeutics Inc.’s share owned by insiders are 0.5%. Insiders Comparatively, owned 8.4% of Melinta Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
vTv Therapeutics Inc. -10% -21.6% 41.51% 95.65% -60.18% -15.09%
Melinta Therapeutics Inc. -13.45% 22.01% -55.22% -77.61% -92.23% 29.94%

For the past year vTv Therapeutics Inc. has -15.09% weaker performance while Melinta Therapeutics Inc. has 29.94% stronger performance.

Summary

vTv Therapeutics Inc. beats on 6 of the 10 factors Melinta Therapeutics Inc.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The companyÂ’s drug candidate for the treatment of AlzheimerÂ’s disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. Its type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. operates as a subsidiary of M&F TTP Holdings Two LLC.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.